336 related articles for article (PubMed ID: 33591962)
1. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
Jæger KH; Wall S; Tveito A
PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
[TBL] [Abstract][Full Text] [Related]
2. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
[TBL] [Abstract][Full Text] [Related]
3. A computational method for identifying an optimal combination of existing drugs to repair the action potentials of SQT1 ventricular myocytes.
Jæger KH; Edwards AG; Giles WR; Tveito A
PLoS Comput Biol; 2021 Aug; 17(8):e1009233. PubMed ID: 34383746
[TBL] [Abstract][Full Text] [Related]
4. Drug Testing in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
Zhao Z; Li X; El-Battrawy I; Lan H; Zhong R; Xu Q; Huang M; Liao Z; Lang S; Zimmermann WH; Cyganek L; Wieland T; Akin I; Zhou XB; Borggrefe M
Clin Pharmacol Ther; 2019 Sep; 106(3):642-651. PubMed ID: 30947366
[TBL] [Abstract][Full Text] [Related]
5. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
[TBL] [Abstract][Full Text] [Related]
6. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
[TBL] [Abstract][Full Text] [Related]
7. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
8. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
[TBL] [Abstract][Full Text] [Related]
10. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
[TBL] [Abstract][Full Text] [Related]
12. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
[TBL] [Abstract][Full Text] [Related]
14. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.
Odening KE; Bodi I; Franke G; Rieke R; Ryan de Medeiros A; Perez-Feliz S; Fürniss H; Mettke L; Michaelides K; Lang CN; Steinfurt J; Pantulu ND; Ziupa D; Menza M; Zehender M; Bugger H; Peyronnet R; Behrends JC; Doleschall Z; Zur Hausen A; Bode C; Jolivet G; Brunner M
Eur Heart J; 2019 Mar; 40(10):842-853. PubMed ID: 30496390
[TBL] [Abstract][Full Text] [Related]
15. Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
Huang M; Liao Z; Li X; Yang Z; Fan X; Li Y; Zhao Z; Lang S; Cyganek L; Zhou X; Akin I; Borggrefe M; El-Battrawy I
Front Pharmacol; 2021; 12():675003. PubMed ID: 34025432
[No Abstract] [Full Text] [Related]
16. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
17. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
[TBL] [Abstract][Full Text] [Related]
18. Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes.
Chen Z; Xian W; Bellin M; Dorn T; Tian Q; Goedel A; Dreizehnter L; Schneider CM; Ward-van Oostwaard D; Ng JK; Hinkel R; Pane LS; Mummery CL; Lipp P; Moretti A; Laugwitz KL; Sinnecker D
Eur Heart J; 2017 Jan; 38(4):292-301. PubMed ID: 28182242
[TBL] [Abstract][Full Text] [Related]
19. Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.
Shinozawa T; Nakamura K; Shoji M; Morita M; Kimura M; Furukawa H; Ueda H; Shiramoto M; Matsuguma K; Kaji Y; Ikushima I; Yono M; Liou SY; Nagai H; Nakanishi A; Yamamoto K; Izumo S
Stem Cell Reports; 2017 Feb; 8(2):226-234. PubMed ID: 28111276
[TBL] [Abstract][Full Text] [Related]
20. Modelling the effects of quinidine, disopyramide, and E-4031 on short QT syndrome variant 3 in the human ventricles.
Luo C; Wang K; Zhang H
Physiol Meas; 2017 Sep; 38(10):1859-1873. PubMed ID: 28812984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
